The Crucial Function of Triheptanoin in Metabolic Disorders
•
3 min read
Triheptanoin, marketed as Dojolvi, received FDA approval in 2020 as a groundbreaking treatment for patients with long-chain fatty acid oxidation disorders (LC-FAOD). The primary function of triheptanoin is to serve as an alternative energy substrate, providing a crucial source of calories and fatty acids for individuals unable to metabolize long-chain fats effectively.
